The US Patent and Trademark Office has patented Australian cell therapy company Chimeric Therapeutics' (ASX:CHM) CHM 0201 (CORE-NK) technology.
The technology is used to manufacture Chimeric’s clinical-stage universal NK cell asset CHM 0201 and preclinical-stage NK cell assets CHM 0301, CHM 1301, and CHM 2301.
The allowed patent application 16/614,132, entitled 'Compositions for Expanding Natural Killer Cells', is expected to provide patent protection until 2039.
Chimeric holds the exclusive worldwide license to develop and commercialise the allowed patent and related patent applications filed in other global territories for oncology, immune disorders, and infectious diseases.
Chimeric’s CEO and managing director, Jennifer Chow, said, “We are delighted with USPTO’s decision to grant patent protection for our CORE-NK platform in the United States, the single largest global market for biopharmaceutical products. The allowance of this first US patent application lays the foundation for the intellectual property portfolio supporting our best-in-class pipeline of allogeneic NK cell assets.”